NCT05558982 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05558982
Title	BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (EXPEL PANC)
Acronym	EXPEL PANC
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Georgetown University
Indications	pancreatic ductal adenocarcinoma
Therapies	Pembrolizumab + Talabostat mesylate
Age Groups:	senior \| adult
Covered Countries	USA

Filter rows:

Showing 1 to 3 of 3 entries

Facility	Status	City	State	Zip	Country	Details
Georgetown Lombardi Comprehensive Cancer Center	RECRUITING	Washington	District of Columbia	20007	United States	Details
John Theurer Cancer Center at Hackensack University Medical Center	RECRUITING	Hackensack	New Jersey	07601	United States	Details
Medstar Washington Hospital Center	RECRUITING	Washington	District of Columbia	20010	United States	Details

Showing 1 to 3 of 3 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT05558982Clinical Trial Detail